Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice

BACKGROUND: Approximately 1–2% of patients with non‒small-cell lung cancer (NSCLC) harbor ROS1 rearrangements. Crizotinib, an oral small-molecule tyrosine kinase inhibitor (TKI) that targets anaplastic lymphoma kinase (ALK), MET, and ROS1, has shown marked antitumor activity in patients with ROS1-po...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chang, Yu, Hui, Chang, Jianhua, Chen, Haiquan, Li, Yuan, Zhao, Weixin, Zhao, Kuaile, Zhu, Zhengfei, Sun, Si, Fan, Min, Wang, Jialei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602983/
https://www.ncbi.nlm.nih.gov/pubmed/30976989
http://dx.doi.org/10.1007/s11523-019-00636-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602983/
https://www.ncbi.nlm.nih.gov/pubmed/30976989
http://dx.doi.org/10.1007/s11523-019-00636-6

Ejemplares similares